Table 1.

Participant characteristics and medical history according to interviewed groups

Characteristics	All women (n = 30)	Group 1 (n = 10)	Group 2 (n = 10)	Group 3 (n = 10)
Age, years	50 (9)	52 (14)	50 (7)	50 (8)
Australian state or territory, n (%)
Australian Capital Territory	2 (7)	1 (10)	1 (10)	0 (0)
New South Wales	6 (20)	2 (20)	2 (20)	2 (20)
Northern Territory	1 (3)	0 (0)	1 (10)	0 (0)
Queensland	4 (13)	1 (10)	1 (10)	2 (20)
South Australia	4 (13)	3 (30)	1 (10)	0 (0)
Tasmania	2 (7)	1 (10)	0 (0)	1 (10)
Victoria	6 (20)	1 (10)	2 (20)	3 (30)
Western Australia	5 (17)	1 (10)	2 (20)	2 (20)
Body mass index, kg/m2	30 (5)	29 (6)	30 (4)	30 (5)
Parity	2 (1)	1.5 (1)	2 (1)	2.5 (1)
Years since diagnosis	4 (3)	1 (1)	3 (1)	8 (3)
Menopausal status, n (%)
Pre	1 (3)	1 (10)	0 (0)	0 (0)
Peri	8 (27)	2 (20)	3 (30)	3 (30)
Post	21 (70)	7 (70)	7 (70)	7 (70)
Breast cancer stage, n (%)
I	2 (6)	1 (10)	1 (10)	0 (0)
II	12 (40)	6 (60)	4 (40)	2 (20)
III	11 (37)	3 (30)	2 (20)	6 (60)
IV	5 (17)	0 (0)	3 (30)	2 (20)
Breast cancer treatment, n (%)*
Surgery	24 (80)	5 (50)	9 (90)	10 (100)
Chemotherapy	23 (77)	8 (80)	7 (70)	8 (80)
Radiotherapy	20 (67)	5 (50)	6 (60)	9 (90)
Tamoxifen	13 (43)	3 (30)	4 (40)	6 (60)
Aromatase inhibitors	14 (47)	5 (50)	4 (40)	5 (50)
Presence of pelvic floor dysfunction, n (%)*
Urinary incontinence	24 (80)	7 (70)	8 (80)	9 (90)
Faecal incontinence	6 (20)	2 (20)	3 (30)	1 (10)
Sexual dysfunction	20 (67)	7 (70)	6 (60)	7 (70)

Group 1, currently undergoing primary cancer treatment. Group 2, completed primary cancer treatment. Group 3, reached survivorship milestone

All data presented are mean (standard deviation) unless stated otherwise

^*Multiple options were allowed to be selected